STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) Meeting Abstract

  

Authors:	Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Abstract Title:	STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
Meeting Title:	2023 ASCO Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	6 Suppl.
Meeting Dates:	2023 Feb 16-18
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-02-20
Language:	English
DOI:	10.1200/JCO.2023.41.6_suppl.TPS752
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=162007101&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting Abstract: TPS752 -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/203757